dr. papadimitrakopoulou provides an update on pembrolizumab for lung cancer
Published 9 years ago • 537 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
0:56
dr. papadimitrakopoulou on role of immunotherapy in lung cancer
-
1:30
dr. papadimitrakopoulou on impactful targeted therapies in lung cancer
-
1:53
dr. papadimitrakopoulou on immunotherapy combinations in lung cancer
-
1:00
dr. papadimitrakopoulou on adverse events associated with immunotherapy in lung cancer
-
1:51
dr. papadimitrakopoulou on biomarker-driven clinical trials in nsclc
-
1:31
dr. papadimitrakopoulou on importance of more targeted therapies in nsclc
-
4:39
chemotherapy pembrolizumab: a new standard of care?
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
2:36
dr. papadimitrakopoulou discusses the lung-map trial
-
6:12
advances in intratumoral therapy and an update on the bdb001-102 trial
-
0:53
dr. sequist on pembrolizumab monotherapy in nonsquamous nsclc
-
1:23
dr. liu on the potential of pembrolizumab in sclc
-
5:00
implications for pembrolizumab in nsclc
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc
-
1:03
dr. rizvi discusses pembrolizumab for non-small cell lung cancer
-
0:36
dr. camidge on the fda approval of pembrolizumab for squamous nsclc
-
1:28
dr. wolchok on an updated analysis of pembrolizumab (mk-3475) for melanoma
-
4:22
advancing the treatment of nondriver metastatic nsclc
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc